Join
Live feed
·
PRReleasevia Quantisnow
Cassava Sciences Inc. logo

Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer's Disease in the Journal of Prevention of Alzheimer's Disease

ByQuantisnow·Wall Street's wire, on your screen.
SAVA· Cassava Sciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SAVA (Cassava Sciences Inc.) and more on Quantisnow.